Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company specializing in curative targeted cell therapies for autoimmune diseases, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company will engage in a fireside chat on March 3, 2025, at 11:50 a.m. ET in Boston, MA.
Interested parties can access a live webcast of the presentation through the News and Events section on www.cabalettabio.com. The presentation recording will remain available for replay on the company's website for 30 days following the event.
Cabaletta Bio (Nasdaq: CABA), un'azienda biotecnologica in fase clinica specializzata in terapie cellulari mirate curative per malattie autoimmuni, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. L'azienda parteciperà a una chiacchierata informale il 3 marzo 2025, alle 11:50 ET a Boston, MA.
Le parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione News ed Eventi su www.cabalettabio.com. La registrazione della presentazione sarà disponibile per la visione per 30 giorni dopo l'evento sul sito web dell'azienda.
Cabaletta Bio (Nasdaq: CABA), una empresa de biotecnología en etapa clínica especializada en terapias celulares curativas dirigidas para enfermedades autoinmunes, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La empresa participará en una charla informal el 3 de marzo de 2025, a las 11:50 a.m. ET en Boston, MA.
Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Noticias y Eventos en www.cabalettabio.com. La grabación de la presentación estará disponible para su reproducción en el sitio web de la empresa durante 30 días después del evento.
카발레타 바이오 (Nasdaq: CABA), 자가면역 질환을 위한 치료적 표적 세포 치료에 전문화된 임상 단계의 생명공학 회사가 TD Cowen 제45회 연례 건강 관리 회의에 참여한다고 발표했습니다. 이 회사는 2025년 3월 3일 오전 11시 50분 ET에 매사추세츠주 보스턴에서 진행되는 화상 대화에 참여할 예정입니다.
관심 있는 분들은 www.cabalettabio.com의 뉴스 및 이벤트 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 발표 녹화는 행사 후 30일 동안 회사 웹사이트에서 재생할 수 있습니다.
Cabaletta Bio (Nasdaq: CABA), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies cellulaires ciblées curatives pour les maladies auto-immunes, a annoncé sa participation à la 45e Conférence Annuelle de Santé de TD Cowen. L'entreprise participera à une discussion informelle le 3 mars 2025 à 11h50 ET à Boston, MA.
Les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Actualités et Événements sur www.cabalettabio.com. L'enregistrement de la présentation sera disponible en replay sur le site de l'entreprise pendant 30 jours après l'événement.
Cabaletta Bio (Nasdaq: CABA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf kurative gezielte Zelltherapien für Autoimmunerkrankungen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Das Unternehmen wird am 3. März 2025 um 11:50 Uhr ET in Boston, MA, an einem informellen Gespräch teilnehmen.
Interessierte Parteien können über den Bereich Nachrichten und Veranstaltungen auf www.cabalettabio.com auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:50 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
FAQ
When is Cabaletta Bio (CABA) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Cabaletta Bio's (CABA) TD Cowen conference presentation?
What type of therapies is Cabaletta Bio (CABA) developing?
How long will Cabaletta Bio's (CABA) TD Cowen conference presentation be available for replay?
